Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis
Autor: | Xiao-Feng Zhang, Wei-Dong Wang, Xiao-Kai Wang, Jin-Feng Sun, Yu-Jun Tang, Xiao-Xian Guan, Jian-Ming Fan |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
medicine.medical_specialty Synbiotics Medicine (miscellaneous) 030209 endocrinology & metabolism Gut flora digestive system Gastroenterology Inflammatory bowel disease law.invention 03 medical and health sciences Probiotic 0302 clinical medicine Randomized controlled trial law Internal medicine Lactobacillus Medicine Humans Bifidobacterium 030109 nutrition & dietetics Nutrition and Dietetics biology business.industry Probiotics biology.organism_classification medicine.disease Inflammatory Bowel Diseases Ulcerative colitis digestive system diseases Gastrointestinal Microbiome Prebiotics business |
Zdroj: | European journal of nutrition. 60(5) |
ISSN: | 1436-6215 |
Popis: | Probiotics have been reported to be beneficial for inflammatory bowel disease (IBD), but the types, number of strains, dosage, and intervention time of probiotics used remain controversial. Furthermore, the changes of gut microbiota in IBD’s patients are also intriguing. Thus, this meta-analysis was to explore the clinical effects and gut microbiota changes of using probiotics, prebiotics and synbiotics in IBD. The search was performed in PubMed, Web of Science and the Cochrane library from inception to April 2020. Qualified randomized controlled trials were included. IBD’s remission rate, disease activity index and recurrence rate were extracted and analyzed. Changes in the gut microbiota of patients with IBD are comprehensively described. Thirty-eight articles were included. Probiotics, prebiotics and synbiotics can induce/maintain IBD’s remission and reduce ulcerative colitis (UC) disease activity index (RR = 1.13, 95% CI 1.02, 1.26, P |
Databáze: | OpenAIRE |
Externí odkaz: |